Compare Amphastar Pharmaceuticals Inc (AMPH) vs Target Corporation (TGT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Target Corporation — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Target Corporation trades at $135.7 (market cap $61.38B). The key difference: Target Corporation is far larger — about 74.3× Amphastar Pharmaceuticals Inc's market cap, and Target Corporation pays a 3.43% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | TGT | |
|---|---|---|
Market Cap | $826.08M | $61.38B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $141.19 |
52-Week Low | $16.87 | $83.68 |
Enterprise Value | $1.22B | $76.68B |
Dividend Yield | — | 3.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Target Corporation (TGT) trades at $135.13, up 2.19% with a bullish technical signal and consistent earnings beats. The stock shows strong fundamentals with a P/E of 17.85, ROE of 22.02%, and positive cash flow trends. Recent corporate restructuring aims to streamline operations while maintaining dividend payments.
Target presents a balanced investment case with solid profitability and analyst consensus near current levels. Upside potential exists toward the $137 price target, though competitive pressures and margin compression remain key risks. The stock offers stability with dividend income but faces retail sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
